Psychedelic Research in
Hungary
Hungary has a restrictive access environment for classic psychedelics. Public guidance and UNODC-linked legal references indicate that psilocybin, LSD, MDMA, ibogaine and related substances are controlled, with no routine medical access outside authorised research or tightly controlled exemptions.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Hungary.
- 1
Hungary's psychedelic profile is mainly restrictive rather than developmental: the evidence points to control and enforcement, not an established domestic therapy market for classic psychedelics.
- 2
The most relevant clinical pathway is ketamine/esketamine for depression, especially TRD, which fits Blossom's linked trial topics better than classic psychedelics.
- 3
Public guidance suggests some hospital-based ketamine infusion use exists, but this is described as limited and institution-specific rather than standardised nationwide care.
- 4
There is an administrative gatekeeping layer for controlled substances in medicine, including specific permissions for import/export and official oversight of narcotics and psychotropics.
- 5
For a country brief, Hungary looks better framed as a tightly regulated, low-trial-count market with modest depression-focused ketamine relevance than as an emerging psychedelic hub.
Research Snapshot
Blossom currently tracks 6 psychedelic clinical trials connected to Hungary.
- Active trials
- 0
- Total trials
- 6
- Stakeholders
- 0
- Events
- 0
None marked active
Country-linked records
No linked stakeholders
No linked events
Top Compounds
- Esketamine(6)
Top Study Topics
- Major Depressive Disorder (MDD)(3)
- Treatment-Resistant Depression (TRD)(3)
Medical Access Snapshot
Hungary maintains a restrictive legal regime for classic psychedelics: most tryptamines, phenethylamines and plant/fungal preparations (psilocybin, DMT, 5-MeO-DMT, MDMA, mescaline, ibogaine, ayahuasca, 2C-X) are controlled and have no routine medical availability outside approved clinical research. Esketamine (Spravato) is authorised in the EU and listed in Hungarian product databases and can be delivered through licensed medical services; reimbursement pathways exist but are limited and administratively gated. Ketamine is legally available as an...
Regulatory Status
Hungary appears to maintain a strict controlled-substances framework for classic psychedelics: the national drug-information pages state that possession, use and trade of drugs such as LSD and psilocybin are prohibited, and UNODC's country legal summary notes generic control of tryptamines and phenethylamines under the 2012 decree. Ketamine is controlled as a medicinal substance with separate medical-use rules and import/export permissions, and esketamine is EU-authorised, but the exact current Hungarian reimbursement and patient-access pathway should be treated cautiously because public sources describe access only in limited institutional settings rather than broad routine availability.
Country Details
- Region
- Europe
- Last updated
- 18 May 2026
Country Report
Medical Only (Private)Medical Access and Reimbursement
Hungary maintains a restrictive legal regime for classic psychedelics: most tryptamines, phenethylamines and plant/fungal preparations (psilocybin, DMT, 5-MeO-DMT, MDMA, mescaline, ibogaine, ayahuasca, 2C-X) are controlled and have no routine medical availability outside approved clinical research...
Open access guide →Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Hungary.